Title | Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. |
Publication Type | Publication |
Year of Publication | 2020 |
Authors | Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG, Mulligan K |
Journal | Clin Infect Dis |
Volume | 70 |
Issue | 4 |
Pagination | 687-691 |
Date Published | 2020 Feb 03 |
ISSN | 1537-6591 |
Keywords | Adolescent, Adult, Anti-HIV Agents, Bone Density, Emtricitabine, HIV Infections, Homosexuality, Male, Humans, Male, Pre-Exposure Prophylaxis, Sexual and Gender Minorities, Tenofovir, Young Adult |
Abstract | <p>Human immunodeficiency virus-seronegative men aged 15-22 years who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks following PrEP discontinuation. Lumbar spine and whole body BMD z-scores remained below baseline 48 weeks off PrEP in participants aged 15-19 years. Clinical Trials Registration. NCT01772823 (ATN 110) and NCT01769456 (ATN 113).</p> |
DOI | 10.1093/cid/ciz486 |
Alternate Journal | Clin Infect Dis |
PubMed ID | 31179503 |
PubMed Central ID | PMC7319267 |